JCB logo
Cytokines in immune regulation
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents
Published 13 May 2002. doi:10.1083/jcb.200107119
This Article
Right arrow Full Text
Right arrow PDF (Full Text)
Right arrow PPT slides of all figures
Right arrow Supplemental Material Index
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JCB
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Welm, B. E.
Right arrow Articles by Rosen, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Welm, B. E.
Right arrow Articles by Rosen, J. M.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
© The Rockefeller University Press, 0021-9525/2002/5/703 $5.00
The Journal of Cell Biology, Volume 157, Number 4, May 13, 2002 703-714

Article

 Inducible dimerization of FGFR1 : development of a mouse model to analyze progressive transformation of the mammary gland



Bryan E. Welm1,2, Kevin W. Freeman2,3, Mercy Chen1, Alejandro Contreras1, David M. Spencer2,3 and Jeffrey M. Rosen1,2

1 Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030
2 Program in Cell and Molecular Biology, Baylor College of Medicine, Houston, TX 77030
3 Department of Immunology, Baylor College of Medicine, Houston, TX 77030

Address correspondence to J.M. Rosen, Dept. of Molecular and Cellular Biology, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030. Tel.: 713-798-6210. Fax: 713-798-8012. E-mail: jrosen{at}faculty.bcm.tmc.edu

To develop an inducible and progressive model of mammary gland tumorigenesis, transgenic mice were generated with a mouse mammary tumor virus–long terminal repeat–driven, conditional, fibroblast growth factor (FGF)–independent FGF receptor (FGFR)1 (iFGFR1) that can be induced to dimerize with the drug AP20187. Treatment of transgenic mice with AP20187 resulted in iFGFR1 tyrosine phosphorylation, increased proliferation, activation of mitogen-activated protein kinase and Akt, and lateral budding. Lateral buds appeared as early as 3 d after AP20187 treatment and initially consisted of bilayered epithelial cells and displayed apical and basolateral polarity appeared after 13 d of AP20187 treatment. Invasive lesions characterized by multicell-layered lateral buds, decreased myoepithelium, increased vascular branching, and loss of cell polarity were observed after 2–4 wk of treatment. These data indicate that acute iFGFR1 signaling results in increased lateral budding of the mammary ductal epithelium, and that sustained activation induces alveolar hyperplasia and invasive lesions.

Key Words: breast cancer; FGFR; inducible dimerization; mammary gland development; angiogenesis


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?




  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents